Sayali T. Patil, Monika Mane, Kshitija S. Desai, Satyajeet R. Jagdale, P. A. Jadhav, Harshada A. Patil
{"title":"Co-Crystallization: Approaches, Characterization and Applications in Drug Delivery","authors":"Sayali T. Patil, Monika Mane, Kshitija S. Desai, Satyajeet R. Jagdale, P. A. Jadhav, Harshada A. Patil","doi":"10.15415/jptrm.2022.102004","DOIUrl":null,"url":null,"abstract":"Co-crystals play a significant role in the pharmaceutical sector. Medicinal co crystals are multicomponent systems with at least one active therapeutic ingredient and the rest of the constituents being pharmaceutically acceptable. Co crystallization of a medicinal material with a coformer is a potential and growing method for improving pharmaceutical performance in areas such as solubility, dissolution profile, pharmacokinetics, and stability.. A key barrier to developing novel API compounds is poor bio availability and water solubility, which can limit the effectiveness of new drugs or prevent their approval for the market. In terms of the significant enhancement in solubility profiles compared to the single- active pharmaceutical ingredients, co-crystals provide a distinct and competitive edge over other traditional approaches.","PeriodicalId":382729,"journal":{"name":"Journal of Pharmaceutical Technology, Research and Management","volume":"124 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Technology, Research and Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15415/jptrm.2022.102004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Co-crystals play a significant role in the pharmaceutical sector. Medicinal co crystals are multicomponent systems with at least one active therapeutic ingredient and the rest of the constituents being pharmaceutically acceptable. Co crystallization of a medicinal material with a coformer is a potential and growing method for improving pharmaceutical performance in areas such as solubility, dissolution profile, pharmacokinetics, and stability.. A key barrier to developing novel API compounds is poor bio availability and water solubility, which can limit the effectiveness of new drugs or prevent their approval for the market. In terms of the significant enhancement in solubility profiles compared to the single- active pharmaceutical ingredients, co-crystals provide a distinct and competitive edge over other traditional approaches.